Benutzerspezifische Werkzeuge

Beendete Studien

Diverse: Merck EMR 200647-001

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.Mehr…

AML/MM: Bayer 18117

An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies.Mehr…

Diverse: Glenmark

A Phase 1, first-in-man, multicenter, open-label, dose-escalation study of single-agent GBR 1302 in subjects with HER2 positive cancers.Mehr…

MDS: Philogen PH-F16IL2CD33-03/15

A Phase I study of the tumor-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with the anti-CD33 antibody BI 836858 in patients with AML relapse after allogeneic hematopoietic stem cell transplantation.Mehr…

NHL/ DLBCL: Roche BH39147-NHL-DLBCL

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL).Mehr…

NHL: Zuma 7

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)Mehr…

AML: Novartis CPDR001X2105

Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic Syndrome.Mehr…

AML: H3 Biomedicine

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia.Mehr…

MDS: Abbvie M15-522

A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure.Mehr…

Diverse: EMR 100036-002

First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaMehr…

Urothel: Daiichi Sankyo DS8201-A-U105

A phase 1b, multicenter, two-part, open-label study of Trastuzumab Deruxtecan, an anti-human epidermal growth factor receptor-2 (HER2)-Antibody drug conjugate(ADC), in combination with Nivolumab, an anti-PD-1 Antibody, for subjects with HER2-expressing advanced breast and ...Mehr…

HNSCC: AstraZeneca D5660C00004

A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 ...Mehr…

Diverse: MSD MK4621-002

A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination with Pembrolizumab (MK-3475) in Participants with advanced/Metastatic or Recurrent Solid Tumors.Mehr…